Why Choose OLYSENSE CAD/AI?

Designed to address unmet needs across upper and lower GI endoscopy, the OLYSENSE CAD/AI platform includes CADDIETM, CADUTM and SMARTIBDTM apps.

OLYSENSE CAD/AI apps aid the detection and characterization of suspected colorectal polyps, detection of dysplasia within Barrett’s esophagus, as well as the characterization of ulcerative colitis.

With the growing availability of CAD/AI solutions, selecting the right one for your practice is crucial. OLYSENSE CAD/AI is designed to address your daily challenges with precision, efficiency and ease of adoption.

  • Increased detection of adenomas: CADDIETM increases adenoma detection by 7.4%, aiding CRC prevention.5
  • Increased detection of sessile serrated lesions (SSL) and flat polyps: Endoscopists detect 230% more SSL, and 37% more non polypoid (“flat”) polyps compared to when they do not use CADDIETM.6
  • Increased detection of high-risk polyp size category: Endoscopists detect 136% more large polyps and 93% more large adenomas compared to when they do not use CADDIETM.6
  • Characterization support during colonoscopies: Endoscopists characterize 13.3% more diminutive adenomas than when they do not use CADDIETM.5
  • Detection of dysplasia within Barrett’s esophagus: CADUTM correctly identified 88.16% of patients with dysplastic or neoplastic lesions.7
  • Assistance in the MAYO scoring of ulcerative colitis with SMARTIBDTM.8

Unlocking the Power of Intelligent Endoscopy

Our platform delivers instant image analysis directly on the endoscopy monitor, allowing endoscopists to make informed decisions in real time. Seamless interaction during procedures is supported through hands-free control via a foot pedal, while the apps leverage secure, cloud-based data streaming technology.

Enhancing Endoscopy:
Explore the Three Specialized OLYSENSE CAD/AI Apps


Empowering Clinicians with Connected Intelligence

Upgrade your Olympus endoscopy system with OLYSENSE CAD/AI, and unlock your unmet endoscopy needs. For compatibility with existing systems, please contact Olympus.

Harness the power of artificial intelligence, and enter a new era of seamless, intelligent endoscopy.

Products and technologies shown are not presently available in all countries, and there is no time period established as to when or if these products and/or technologies will be available in market.

EVIS X1 Endoscopy System

Push boundaries of adenoma detection and characterization with EVIS X1’s industry-leading imaging techniques.

Extended Depth of Field (EDOF) — a lens technology providing high image clarity with broad focus and seamless magnification to ultimately improve characterization of abnormalities including polyps.

Texture and Color Enhancement Imaging (TXI) — an enhanced white-light imaging technique that improves both the detection and characterization of adenomas by accentuating differences in texture and color and provides more uniform illumination.

Narrow Band Imaging (NBI) — a blue-light technology that aids in the characterization of adenomas with its ability to visualize micro-capillaries.

Discover EVIS X1

Related Products

Products - Filter by specialty

Downloads

SMARTID eBrochure (PDF, 1.5 MB)

CADDIE eBrochure (PDF, 1.9 MB)

CADU eBrochure (PDF, 1.6 MB)

References
1 Kim NH, Jung YS, Jeong WS, et al. Miss rate of colorectal neoplastic polyps and risk factors for missed polyps in consecutive colonoscopies. Intest Res. 2017;15(3):411-418. doi:10.5217/ir.2017.15.3.411.
2 Lee A, Iskander JM, Gupta N, et al. Queue position in the endoscopic schedule impacts effectiveness of colonoscopy. Am J Gastroenterol. 2011;106(8):1457-1465. doi:10.1038/ajg.2011.87.
3 D. A. Corley et al., “Adenoma Detection Rate and Risk of Colorectal Cancer and Death A BS TR AC T,” n engl j med, vol. 14, no. 3, pp. 1298–306, 2014, doi: 10.1056/ NEJMoa1309086.
4 Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150(3):599- e15. doi:10.1053/j.gastro.2015.11.040.
5 Data on file with Odin Medical Ltd., CADDIETM AI Trial - NCT04325815.
6 Data not peer-reviewed/published at time of document creation, Data on file with Odin Medical Ltd, EAGLE Trial - NCT05730192.
7 Data on file with Odin Medical Ltd, ODIN-CADU-BTR Bench Testing Report - Dysplasia Segmentation and ODIN-CADU-TCP-028 Verification Report V1.4.5.
8 Data on file with Odin Medical Ltd, ODIN-IBD-TCU-003 Validation ReportV1.0.2, ODIN-IBD-TCP-002 Verification ReportV1.0.2.
9 Data not peer-reviewed/published at time of document creation, Data on file with Odin Medical Ltd, EAGLE Trial - NCT05730192.
10 Data on file with Odin Medical Ltd, PrRq-002.
11 Data on file with Odin Medical Ltd, ODIN-CADU-TCP-001 Verification Report V1.4.5, ODIN-CADU-TCP-027 Verification Report V1.4.5, ODIN-CADU-TCP-003 Verification Report V1.4.5, ODIN-CADU-BTR Bench Testing Report - Dysplasia Segmentation.
12 Data on file with Odin Medical Ltd, ODIN-CADU-TCP-001 Verification Report V1.4.5, ODIN-CADU-TCP-027 Verification Report V1.4.5, ODIN-CADU-TCP-003 Verification Report V1.4.5, ODIN-CADU-BTR Bench Testing Report - Dysplasia Segmentation, ODIN-CADU-TCP-028 Verification Report V1.4.5.
13 Data on file with Odin Medical Ltd, ODIN-IBD-TCU-003 Validation ReportV1.0.2, ODIN-IBD-TCP-002 Verification ReportV1.0.2.
14 Data on file with Odin Medical Ltd., TCP-056, TCO-018, FDA-TCP-068, FDA-TCP-064, FDA-TCP-065, FDA-TCP-067